ModerateFirst-generation cephalosporin×Non-steroidal anti-inflammatory drugs (NSAIDs)
Updated · Methodology
Mechanism
Cefalexin is eliminated by the kidneys: more than 90% of a dose is excreted unchanged in the urine within 8 hours, by glomerular filtration and tubular secretion (cefalexin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). CYP2C9 and CYP2C8 metabolise ibuprofen in the liver, and the kidneys excrete its inactive metabolites (ibuprofen SmPC, AEMPS). The documents say nothing about either drug changing the elimination of the other. According to the Spanish cefalexin SmPC, the risk of nephrotoxicity may increase when cefalexin is given with certain other drugs, such as aminoglycosides, other cephalosporins, vancomycin, furosemide and similar potent diuretics (cefalexin SmPC, AEMPS). Non-steroidal anti-inflammatory drugs (NSAIDs) are not on this list. According to the ibuprofen SmPC, however, inhibition of prostaglandins can cause fluid retention and impaired renal function, and long-term use can lead to renal damage (ibuprofen SmPC, AEMPS).
Symptoms
The documents describe no symptoms specific to this combination. Ibuprofen can raise blood creatinine, urea nitrogen and potassium and lower creatinine clearance. Uncommon reactions include tubulointerstitial nephritis, nephrotic syndrome and renal failure, and long-term use can lead to renal papillary necrosis (ibuprofen summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cefalexin rarely causes tubulointerstitial nephritis, and its common adverse reactions are diarrhoea and nausea (cefalexin SmPC, AEMPS).
Management
No document contraindicates the combination, and none addresses it directly. Non-steroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, are used with caution with drugs that can increase the risk of renal dysfunction (ibuprofen summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With certain such drugs, cefalexin may add to the risk of kidney damage (cefalexin SmPC, AEMPS). Ibuprofen is used at the lowest effective dose for the shortest time, with caution in kidney, heart or liver disease, and renal function is monitored during long-term treatment (ibuprofen SmPC, AEMPS). Ibuprofen is contraindicated in severe renal failure, with a glomerular filtration rate below 30 mL/min (ibuprofen SmPC, AEMPS). Cefalexin is given with caution when renal function is markedly impaired. At a filtration rate below 10 mL/min or on dialysis, the daily dose does not exceed 500 mg (cefalexin SmPC, AEMPS). In dehydration, ibuprofen is used with caution, and adequate fluid intake is ensured. Severe dehydration from vomiting, diarrhoea or insufficient fluid intake is a contraindication (ibuprofen SmPC, AEMPS). Diarrhoea is a common adverse reaction to cefalexin (cefalexin SmPC, AEMPS). When ibuprofen is taken for fever or pain related to an infection, the infection is monitored, because ibuprofen can mask its symptoms and delay appropriate treatment (ibuprofen SmPC, AEMPS). The documents give no specific dose adjustment for this combination (ibuprofen and cefalexin SmPCs, AEMPS; ibuprofen and cefalexin labels, US Food and Drug Administration, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Ibuprofeno (Neobrufen 400 mg) (nº registro 70030), secciones 4.3, 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 70030, revisión 02/2026, secciones 4.3, 4.4 y 4.5
- FDA: Ibuprofen tablets, Amneal (ibuprofen) prescribing information (2026)– DailyMed, setid 17577b3b-e755-45d1-8b53-775d058578b2, Amneal Pharmaceuticals, revised 07/2026, Warnings (Renal Effects), Precautions (Drug Interactions: Diuretics)
- AEMPS: Ficha técnica: Cefalexina – Kefloridina Forte 500 mg (nº registro 51115), sección 4.5 (2022)– AEMPS, CIMA, nº registro 51115 (Kefloridina Forte 500 mg cápsulas duras, Stada), revisión 03/2022, secciones 4.2, 4.4, 4.5, 4.8 y 5.2
- AEMPS: Ficha técnica: Cefalexina – Cefalexina Reiwa Healthcare 250 mg (nº registro 88592), sección 4.4 (2024)– AEMPS, CIMA, nº registro 88592 (Cefalexina Reiwa Healthcare 250 mg polvo para suspensión oral EFG), revisión 09/2024, secciones 4.4, 4.5 y 4.8
- FDA: Cephalexin capsules, Teva (cephalexin) prescribing information (2026)– FDA, DailyMed setid 19307ff0-71de-477b-965d-ea243e5ede3a (Teva Pharmaceuticals USA), version 28, revised 08/2026, sections 5, 6.1, 7, 8.6 and 12.3